Shraman Foundation Receives Ownership of Mentrik Biotech, LLC

Plano, Texas (Issuewire.com)  - Shraman Foundation, a Texas Nonprofit Corporation focused on advancing the development, manufacture, and distribution of medicines and therapies to provide accessible treatments globally, announced that it has received exclusive ownership of Mentrik Biotech, LLC (“Mentrik”). 

Mentrik acquired exclusive global rights to its lead asset, ocaratuzumab, from Eli Lilly & Co (“Lilly”) following Lilly’s preceding acquisition of this compound from Applied Molecular Evolution, Inc. 

About Ocaratuzumab 

Ocaratuzumab is a fully humanized, monoclonal antibody targeting CD20.  Inhibition of CD20 has been shown to alleviate a variety of severe chronic auto-immune diseases and cancers including, but not limited to, multiple sclerosis, rheumatoid arthritis (“RA”), chronic lymphocytic leukemia, and follicular lymphoma.  Ocaratuzumab is clinically validated, with initial studies in human with RA and lymphoma, confirming tolerability and optimal dose.  

About Mentrik Biotech, LLC 

Founded in 2010, Mentrik is a privately held clinical stage biotechnology company headquartered in Plano, Texas, USA.  Mentrik is focused on the development of effective and accessible treatments of autoimmune disorders and specific cancers.  

About Shraman Foundation 

Shraman Foundation is a Texas Nonprofit Corporation headquartered in Plano, Texas, USA.  Shraman has an area of focus to advance the development, manufacture, and distribution of medicines and therapies to provide accessible treatments globally.  For additional information, please contact Amitkumar Patel at apatel@shraman.org. 

Media Contact

Shraman Foundation: apatel@shraman.org; http://www.shraman.org/

Categories : Biotech , Non-profit

Tags : Mentrik , Shraman

Shraman Foundation

apatel@shraman.org

http://www.shraman.org/